Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention

American Journal of Health-System Pharmacy

Volumn 60, Issue 12, 2003, Pages 1251-1256

  McCollam, Patrick L ^a   Foster, David A ^b   Riesmeyer, Jeffrey S ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Solucient LLC   (United States)

Author keywords

Abciximab; Angioplasty; Costs; Economics; Eptifibatide; Hospitals; Mortality; Myocardial infarction; Platelet aggregation inhibitors; Tirofiban

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN; ANTITHROMBOCYTIC AGENT; DRUG DERIVATIVE; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; PEPTIDE; TYROSINE;

ACUTE HEART INFARCTION; ADULT; ARTICLE; CLINICAL TRIAL; COMPLICATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DATA BASE; FEMALE; HEALTH CARE COST; HUMAN; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK ASSESSMENT; SURVIVAL RATE; AGED; CASE CONTROL STUDY; COMPARATIVE STUDY; DRUG ANTAGONISM; DRUG COST; ECONOMICS; HEART INFARCTION; HOSPITAL COST; MIDDLE AGED; STATISTICS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNITED STATES;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CASE-CONTROL STUDIES; DRUG COSTS; FEMALE; HOSPITAL COSTS; HOSPITAL MORTALITY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LENGTH OF STAY; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; TREATMENT OUTCOME; TYROSINE; UNITED STATES;

EID: 0141609620     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajhp/60.12.1251     Document Type: Article

References (37)

1. Montalescot G, Barragan P, Wittenberg O et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001; 344:1895-903.
2. Stone GW, Grines CL, Cox DA et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346:957-66.
3. Neumann FJ, Kastrati A, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction. J Am Coll Cardiol. 2000; 35:915-21.
4. Grines CL, Cox DA, Stone GW et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999; 341:1949-56.
5. Anderson HV, Shaw RE, Brindis RG et al. A contemporary overview of percutaneous coronary interventions: the American College of Cardiology-National Cardiovascular Data Registry (ACC-NCDR). J Am Coll Cardiol. 2002; 39:1096-103.
6. Lage MJ, Barber BL, McCollam PL et al. Impact of abciximab versus eptifibatide on hospital length of stay for PCI patients. Cathet Cardiovasc Interv. 2001; 53:296-303.
7. Lage MJ, Barber BL, McCollam PL et al. Impact of abciximab versus tirofiban on hospital length of stay for PCI patients. Cathet Cardiovasc Interv. 2001; 52:298-305.
8. Lage MJ, Barber BL, Bowman L et al. Shorter hospital stays for angioplasty patients who receive abciximab. J Invasive Cardiol. 2000; 12:179-86.
9. Lage MJ, Barber BL, Bala M et al. Association between abciximab and length of stay in intensive care for patients undergoing PCI. Pharmacoeconomics. 2000; 18:581-9.
10. Lage MJ, Barber BL, Bala M et al. A comparison of abciximab use in MCO and non-MCO populations. Am J Manag Care. 2001; 7:53-62.
11. McCollam PL, Lage MJ, Bala M. A comparison of total hospital costs for PCI patients receiving abciximab versus tirofiban. Cathet Cardiovasc Interv. 2001; 54:152-7.
12. Young JK, Foster DA. Cardiovascular procedures in patients with mental disorders. JAMA. 2000; 283:3198-9. Letter.
13. Foster DA, Heller ST, Young JK. Multidrug-resistant Streptococcus pneumoniae. N Engl J Med. 2001; 344:1329. Letter.
14. Sullivan KM, Belay ED, Durbin RE et al. Epidemiology of Reye's syndrome, United States, 1991-1994: comparison of CDC surveillance and hospital admission data. Neuroepidemiology. 2000; 19:338-44.
15. HCIA-Sachs risk-adjusted mortality software - COBOL version 3. Baltimore: HCIA-Sachs; 2000.
16. Forthman MT, Foster DA, Clare MW et al. Benchmarking risk-adjusted complications and mortality: a case study on outcomes assessment. Manag Care Q. 1995; 3:79-84.
17. Iezzoni LI, Daley J, Heeren T et al. Using administrative data to screen hospitals for high complication rates. Inquiry. 1994; 31 (1):40-55.
18. Iezzoni LI, Daley J, Heeren T et al. Identifying complications of care using administrative data. Med Care. 1994; 32:700-15.
19. HCIA-Sachs expected complications software - COBOL version 4. Baltimore: HCIA-Sachs; 2001.
20. California Office of Statewide Health Planning and Development. 1996-1998 Heart attack outcomes report. www.oshpd.cahwnet/gov/HQAD/HIRC/Outcomes/HeartAttacks/index.htm (accessed 2003 Apr 14).
21. Pennsylvania Health Care Cost Containment Council. Cardiac care - focus on heart attack in Pennsylvania. www.phc4.org/reports/pr_heart.htm (accessed (2002 Dec 10).
22. Mark DB, Hlatky MA, Califf RM et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995; 332:1418-24.
23. Kereiakes DJ, Obenchain RL, Barber BL et al. Abciximab provides cost-effective survival advantage in high-volume interventional practice. Am Heart J. 2000; 140:603-10.
24. Peterson ED, DeLong ER, Muhlbaier LH et al. Challenges in comparing risk-adjusted bypass surgery mortality results: results from the Cooperative Cardiovascular Project. J Am Coll Cardiol. 2000; 36:2174-84.
25. Holmes DR, Berger PB, Garratt KN et al. Application of the New York State PTCA mortality model in patients undergoing stent implantation. Circulation. 2000; 102:517-22.
26. Shaw RE, Anderson HV, Brindis RG et al. Development of a risk adjustment mortality model using the American College of Cardiology - National Cardiovascular Data Registry (ACC-NCDR) experience: 1998-2000. J Am Coll Cardiol. 2002; 39:1104-12.
27. Mark DH. Visualizing cost-effectiveness analysis. JAMA. 2002; 287:2428-9. Editorial.
28. Sheehan FH, Braunwald E, Canner P et al. The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. Circulation. 1987; 75:817-29.
29. Neumann F, Blasini R, Schmitt C et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 1998; 98:2695-701.
30. Collet JP, Montalescot G, Lesty C et al. Effects of abciximab on the architecture of platelet-rich clots in patients with acute myocardial infarction undergoing primary coronary intervention. Circulation. 2001; 103:2328-31.
31. Topol EJ, Mark DB, Lincoff AM et al. Outcomes at 1 year and economic implications of platelet glycoprotein-IIb/IIIa blockade in patients undergoing coronary stenting: results from a multicentre randomised trial. Lancet. 1999; 354:2019-24.
32. Cohen DJ, O'Shea JC, Pacchian CM et al. In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT trial). Am J Cardiol. 2002; 89:61-4.
33. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000; 342:1887-92.
34. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000; 342:1878-86.
35. Tcheng J. Abciximab use during percutaneous intervention in patients with acute myocardial infarction improves early and late clinical outcomes: final results of the CADILLAC trial. Paper presented at 50th Annual Scientific Session of the American College of Cardiology. Orlando, FL; 2001 Mar 19.
36. Elad Y, French WJ, Shavelle DM et al. Primary angioplasty and selection bias in patients presenting late after onset of chest pain and ST elevation myocardial infarction. J Am Coll Cardiol. 2002; 39:826-33.
37. Maynard C, Every NR, Chapko MK et al. Improved outcomes associated with stenting in the Healthcare Cost and Utilization Project. J Interv Cardiol. 2001; 14:159-64.